Can’t attend the live streamed version of this workshop? All of our workshops are also available as pre-recorded on-demand videos that you can watch when you want. All are available 10 working days after the live date presentation for up to one year.
Introduction
On Friday April 11, 2025, Liam Modlin will deliver a half-day workshop on the research and experimental use of psychedelics in the treatment of mental health conditions.
Workshop Outline
This workshop will provide mental healthcare professionals with an introduction to the experimental use of psychedelics for the treatment of psychiatric conditions in research settings, including depression and PTSD. Mental health providers will learn about the types of compounds being researched, their proposed indications, potential benefits, and their associated risks and side effects. Through a trauma-informed lens, providers will also learn about the key clinical principles and practices utilized across psychedelic clinical trials. This training will equip providers with the foundational knowledge and understanding necessary to navigate the evolving landscape of psychedelic research and its potential implications for clinical practice.
Learning Objectives
By the end of this workshop, participants will learn to:
Identify and describe a range of psychedelic compounds currently under research, including their basic mechanisms of action and common subjective effects.
Recognize specific psychiatric conditions being investigated for psychedelic therapy and articulate the various treatment models and protocols used in clinical trials.
Understand the potential therapeutic benefits of psychedelics while critically evaluating the associated risks, side effects, and contraindications to promote safe application in clinical research settings.
Apply key clinical principles of psychedelic therapy, including effective preparation, psychological support during treatment sessions, and methods for facilitating emotional processing and integrating insights after treatment.
About the Presenter
Nadav Liam Modlin (MSc) is a psychological therapist, therapist trainer/supervisor, and lecturer at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London. With an interest in psychopharmacology and clinical expertise in treating trauma and complex mental-health conditions, at the IoPPN Liam works as a research therapist and clinical investigator on studies exploring the safety and efficacy of psychedelics. An experienced therapist trainer and supervisor in psychedelics, Liam also conducts trauma-focused qualitative research investigating patients' perspectives around currently available and psychedelic treatments for psychological trauma and associated psychiatric disorders. His lectures at the IoPPN explore therapeutic models of care in clinical trials investigating the safety and efficacy of psychedelics, the potential applications of psychedelic therapy in military populations and psychotherapy in patients with complex needs. He is also the co-founder of the Maudsley Psychedelic Society Harm Reduction 'Integration' Group.
Training Modalities
Didactic content, Q&A, and videos.
Who should attend
This training workshop on psychedelic therapy is suitable for intermediate to advanced mental health professionals, including psychologists, psychiatrists, social workers, counsellors and mental health nurses. Participants should ideally have a foundational understanding of different treatment modalities and clinical experience in mental health settings. The workshop will build on existing knowledge and skills, focusing on highlighting key theoretical and clinical principles of psychedelic therapy across clinical trials, explore patient and clinician experience of the treatment and discuss ethical considerations in this emerging field of research.
Continuing Education (CE) Credits
Bespoke Mental Health Canada is approved by the Canadian Psychological Association to offer continuing education for psychologists. Bespoke Mental Health Canada maintains responsibility for the program.
After viewing this workshop live, participants have the option to complete an evaluation form in order to be eligible to receive a certificate confirming the number of credits awarded. This certificate will be sent via email.
Participants who view this workshop as a pre-recorded event will need to complete an additional content-related workshop knowledge quiz in order to be eligible to receive CE credits.
Participants who complete this workshop are eligible to receive 3 CE credits.
Fees
Professionals: $100 CAD + tax
Students*: $80 CAD + tax
* Proof of student status may be required in order to qualify for a student rate.
Key References
Yao, Y., Guo, D., Lu, T. S., Liu, F. L., Huang, S. H., Diao, M. Q., Li, S. X., Zhang, X. J., Kosten, T. R., Shi, J., Bao, Y. P., Lu, L., & Han, Y. (2024). Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry research, 335, 115886.
Vollenweider, F. X., & Smallridge, J. W. (2022). Classic Psychedelic Drugs: Update on Biological Mechanisms. Pharmacopsychiatry, 55(3), 121–138.
Johnson, M., Richards, W., & Griffiths, R. (2008). Human hallucinogen research: guidelines for safety. Journal of psychopharmacology (Oxford, England), 22(6), 603–620.
Modlin, N. L., Creed, M., Sarang, M., Maggio, C., Rucker, J. J., & Williamson, V. (2024). Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions. Neuropsychiatric disease and treatment, 20, 109–135.
Kishon, R., Modlin, N. L., Cycowicz, Y. M., Mourtada, H., Wilson, T., Williamson, V., Cleare, A., & Rucker, J. (2024). A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials. NPJ Mental Health Research, 3(1), 33.
Modlin, N. L., Miller, T. M., Rucker, J. J., Kirlic, N., Lennard-Jones, M., Schlosser, D., & Aaronson, S. T. (2023). Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation. Journal of affective disorders, 326, 18–25.
More information coming soon.